A New Highly Concentrated Insulin Aspart AT278 (500 U/ mL ) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI
Authors' conclusion
AT278-U500 maintains its ultra-rapid onset characteristics independent of BMI, representing the first ultra-rapid U500 option for prandial dosing in insulin-resistant people with type 2 diabetes requiring high-dose therapy.
Study context
- Population
- Overweight and obese people with T2D (BMI 25.0–38.7 kg/m²)crossover
- Participants
- 41 participants
- Comparison
- AT278-U500 vs InsAsp-U100 vs HumIns-U500
Methodological detailssingle-centre, double-blind, 12-h euglycaemic clamp, HumIns-U500 studied consecutively open label in a 24-h clamp
- Single-centre
- Double-blind
- 12-h euglycaemic clamp
- HumIns-U500 studied consecutively open label in a 24-h clamp
Primary result
As reported in the abstract
Early glucose-lowering effect (AUCGIR,0-60min) · first hour
Treatment ratio (95% CI)
AT278-U500vs InsAsp-U100
2.02(1.64–2.50)
AT278-U500vs HumIns-U500
3.91(2.89–5.27)
Further findings
Insulin absorption (t Early50%Cmax)
Insulin absorption (t Early50%Cmax)
- AT278-U500 significantly faster insulin absorption than InsAsp-U100 and HumIns-U500
AUCGIR,0-60min by median BMI (29.7 kg/m²) subgroups
- Significantly higher with AT278-U500 vs InsAsp-U100 in both low-BMI and high-BMI subgroups
Linear regression of BMI vs AUCGIR,0-60min
- Significant inverse relationship for InsAsp-U100 (slope)
- −0.142, p < 0.0001
- No such relationship for AT278-U500
Overall insulin exposure and overall glucose-lowering effect
- Overall insulin exposure similar for AT278-U500 and InsAsp-U100
- Overall glucose-lowering effect comparable across all three treatments
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
A New Highly Concentrated Insulin Aspart AT278 (500 U/ mL ) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI. Diabetes Obes Metab. Published 30 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →